{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T01:13:26Z","timestamp":1788484406348,"version":"build-2803163510"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014261","name":"NIHCM Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014261","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006827","name":"Florida Department of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006827","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"DOD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.canlet.2026.218736","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T23:07:52Z","timestamp":1784588872000},"page":"218736","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Multifunctional nano-vaccines integrating lipid-conjugated tumor antigens with TLR\/STING agonists enhance cancer immunotherapy"],"prefix":"10.1016","volume":"658","author":[{"given":"Hari Krishnareddy","family":"Rachamala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naga Malleswara Rao","family":"Nakka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramcharan Singh","family":"Angom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Nandani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zain","family":"Toiemie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward S.","family":"Famularo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamit Kumar","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3579-4317","authenticated-orcid":false,"given":"Santanu","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4006-213X","authenticated-orcid":false,"given":"Krishnendu","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9932-4467","authenticated-orcid":false,"given":"Keith L.","family":"Knutson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debabrata","family":"Mukhopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2026.218736_bib1","doi-asserted-by":"crossref","DOI":"10.1038\/s41417-025-00931-7","article-title":"Barriers and solutions for CAR-T therapy in solid tumors","author":"Tu","year":"2025","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.canlet.2026.218736_bib2","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12943-025-02305-x","article-title":"Advances in cancer immunotherapy: historical perspectives, current developments, and future directions","volume":"24","author":"Zhang","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2026.218736_bib3","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","article-title":"Cold and hot tumors: from molecular mechanisms to targeted therapy","volume":"9","author":"Wu","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2026.218736_bib4","doi-asserted-by":"crossref","DOI":"10.1038\/s41423-025-01316-4","article-title":"Eliciting antitumor immunity via therapeutic cancer vaccines","author":"Peng","year":"2025","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.canlet.2026.218736_bib5","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41541-025-01118-9","article-title":"Multi-disciplinary approaches paving the way for clinically effective peptide vaccines for cancer","volume":"10","author":"Shah","year":"2025","journal-title":"npj Vaccines"},{"key":"10.1016\/j.canlet.2026.218736_bib6","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nri.2017.131","article-title":"Towards personalized, tumour-specific, therapeutic vaccines for cancer","volume":"18","author":"Hu","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.canlet.2026.218736_bib7","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1158\/0008-5472.CAN-13-2564","article-title":"Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody","volume":"74","author":"Karyampudi","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218736_bib8","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41392-024-02107-5","article-title":"Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines","volume":"10","author":"Xiao","year":"2025","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2026.218736_bib9","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13045-025-01670-w","article-title":"Cancer vaccines: current status and future directions","volume":"18","author":"Zhou","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2026.218736_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2025.115675","article-title":"Challenges and opportunities on achieving an adequate delivery efficiency and immunogenicity with peptide-based anticancer vaccines","volume":"225","author":"Wang","year":"2025","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.canlet.2026.218736_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2025.123294","article-title":"STING-activating layered double hydroxide nano-adjuvants for enhanced cancer immunotherapy","volume":"321","author":"Jia","year":"2025","journal-title":"Biomaterials"},{"key":"10.1016\/j.canlet.2026.218736_bib12","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41573-021-00163-y","article-title":"Emerging concepts in the science of vaccine adjuvants","volume":"20","author":"Pulendran","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2026.218736_bib13","first-page":"13","article-title":"Revolutionizing nanovaccines: a new era of immunization","author":"Saleh","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.canlet.2026.218736_bib14","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s40164-025-00656-1","article-title":"Developments in nanotechnology approaches for the treatment of solid tumors","volume":"14","author":"Venturini","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2026.218736_bib15","doi-asserted-by":"crossref","first-page":"14791","DOI":"10.1021\/acsami.2c01087","article-title":"Self-assembly of soluplus in aqueous solutions: characterization and prospectives on perfume encapsulation","volume":"14","author":"Sofroniou","year":"2022","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.canlet.2026.218736_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26041499","article-title":"Soluplus(\u00ae)-Based pharmaceutical formulations: recent advances in drug delivery and biomedical applications","volume":"26","author":"Guembe-Michel","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2026.218736_bib17","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1002\/jps.21176","article-title":"Chemical degradation of peptides and proteins in PLGA: a review of reactions and mechanisms","volume":"97","author":"Houchin","year":"2008","journal-title":"J. Pharmaceut. Sci."},{"key":"10.1016\/j.canlet.2026.218736_bib18","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1007\/s13346-022-01182-x","article-title":"Soluplus(\u00ae) polymeric nanomicelles improve solubility of BCS-class II drugs","volume":"12","author":"Pignatello","year":"2022","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.canlet.2026.218736_bib19","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41541-022-00484-y","article-title":"Lipid A analog CRX-527 conjugated to synthetic peptides enhances vaccination efficacy and tumor control","volume":"7","author":"Tondini","year":"2022","journal-title":"npj Vaccines"},{"key":"10.1016\/j.canlet.2026.218736_bib20","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1021\/acs.bioconjchem.1c00258","article-title":"Lipopeptides for vaccine development","volume":"32","author":"Hamley","year":"2021","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.canlet.2026.218736_bib21","article-title":"A TLR9 agonist enhances the anti-tumor immunity of peptide and lipopeptide vaccines via different mechanisms","volume":"5","author":"Song","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2026.218736_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2025.123539","article-title":"A leucine derivate-adjuvanted LNP vaccine enhances antitumor immunity through mTOR activation and metabolic reprograming in dendritic cells","volume":"325","author":"Zhou","year":"2026","journal-title":"Biomaterials"},{"key":"10.1016\/j.canlet.2026.218736_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112238","article-title":"Agonist and antagonist ligands of toll-like receptors 7 and 8: ingenious tools for therapeutic purposes","volume":"193","author":"Patinote","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.canlet.2026.218736_bib24","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00018-024-05191-6","article-title":"cGAS-STING pathway mediates activation of dendritic cell sensing of immunogenic tumors","volume":"81","author":"Li","year":"2024","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.canlet.2026.218736_bib25","article-title":"Progress update on STING agonists as vaccine adjuvants","volume":"13","author":"Shen","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.canlet.2026.218736_bib26","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41392-023-01557-7","article-title":"Vaccine adjuvants: mechanisms and platforms","volume":"8","author":"Zhao","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2026.218736_bib27","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1038\/nm.3409","article-title":"Key roles of adjuvants in modern vaccines","volume":"19","author":"Reed","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218736_bib28","doi-asserted-by":"crossref","first-page":"4800","DOI":"10.1016\/j.vaccine.2012.05.017","article-title":"A totally synthetic lipopeptide-based self-adjuvanting vaccine induces neutralizing antibodies against heat-stable enterotoxin from enterotoxigenic Escherichia coli","volume":"30","author":"Zeng","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.canlet.2026.218736_bib29","article-title":"Advancements and challenges in peptide-based cancer vaccination: a multidisciplinary perspective","volume":"12","author":"Liu","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.canlet.2026.218736_bib30","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13045-022-01247-x","article-title":"Cancer vaccines as promising immuno-therapeutics: platforms and current progress","volume":"15","author":"Liu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2026.218736_bib31","doi-asserted-by":"crossref","first-page":"7807","DOI":"10.7150\/thno.37194","article-title":"Peptide-based materials for cancer immunotherapy","volume":"9","author":"Zhang","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.canlet.2026.218736_bib32","doi-asserted-by":"crossref","DOI":"10.37349\/etat.2025.1002313","article-title":"Neoantigen-based immunotherapy: advancing precision medicine in cancer and glioblastoma treatment through discovery and innovation","volume":"6","author":"Naffaa","year":"2025","journal-title":"Explor Target Antitumor Ther."},{"key":"10.1016\/j.canlet.2026.218736_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2024.101324","article-title":"Cancer vaccines: target antigens, vaccine platforms and preclinical models","volume":"101","author":"Ruzzi","year":"2025","journal-title":"Mol. Aspect. Med."},{"key":"10.1016\/j.canlet.2026.218736_bib34","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41416-023-02474-w","article-title":"Efficacy of GV1001 with gemcitabine\/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin levels (KG4\/2015): an open-label, randomised, Phase 3 trial","volume":"130","author":"Jo","year":"2024","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218736_bib35","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1056\/NEJMoa1012863","article-title":"gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma","volume":"364","author":"Dj","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218736_bib36","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1391972","article-title":"Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma","volume":"7","author":"Dutoit","year":"2018","journal-title":"OncoImmunology"},{"key":"10.1016\/j.canlet.2026.218736_bib37","series-title":"Translational Immunotherapy of Brain Tumors","first-page":"213","article-title":"Chapter 9 - peptide-specific vaccines","author":"Roth","year":"2017"},{"key":"10.1016\/j.canlet.2026.218736_bib38","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S1470-2045(16)30196-6","article-title":"Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial","volume":"17","author":"Rini","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2026.218736_bib39","doi-asserted-by":"crossref","first-page":"220","DOI":"10.4111\/icu.2017.58.4.220","article-title":"Novel immunotherapy in metastatic renal cell carcinoma","volume":"58","author":"Cho","year":"2017","journal-title":"Investig. Clin. Urol."},{"key":"10.1016\/j.canlet.2026.218736_bib40","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3390\/vaccines13030314","article-title":"Anti-tumor efficacy of a mesothelin-based nanovaccine in a KPC orthotopic mouse model of pancreatic cancer","volume":"13","author":"Ferrari","year":"2025","journal-title":"Vaccines"},{"key":"10.1016\/j.canlet.2026.218736_bib41","doi-asserted-by":"crossref","first-page":"787","DOI":"10.3389\/fbioe.2020.00787","article-title":"Lipidation approaches potentiate adjuvant-pulsed immune surveillance: a design rationale for cancer nanovaccine","volume":"8","author":"Wang","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.canlet.2026.218736_bib42","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/ijc.10186","article-title":"Lipopeptide\u2010based melanoma cancer vaccine induced a strong MART\u201027\u201035\u2010cytotoxic T lymphocyte response in a preclinal study","volume":"98","author":"Le Gal","year":"2002","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218736_bib43","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.3390\/ijms26041499","article-title":"Soluplus\u00ae-based pharmaceutical formulations: recent advances in drug delivery and biomedical applications","volume":"26","author":"Guembe-Michel","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2026.218736_bib44","article-title":"Th17-inducing dendritic cell vaccines stimulate effective CD4 T cell-dependent antitumor immunity in ovarian cancer that overcomes resistance to immune checkpoint blockade","volume":"11","author":"Yan","year":"2023","journal-title":"J. ImmunoTher. Cancer"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526005008?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526005008?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:43:09Z","timestamp":1788482589000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383526005008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":44,"alternative-id":["S0304383526005008"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218736","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multifunctional nano-vaccines integrating lipid-conjugated tumor antigens with TLR\/STING agonists enhance cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218736","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"218736"}}